EC - Novavax Q2 Earnings Preview

Novavax (NASDAQ:NVAX) is scheduled to announce Q2 earnings results on Thursday, August 5th, after market close. The consensus EPS Estimate is -$3.25 and the consensus Revenue Estimate is $387.87M. Over the last 1 year, NVAX has beaten EPS estimates 25% of the time and has beaten revenue estimates 75% of the time. In June, Seeking Alpha contributor JR Research opined that Moderna and Novavax are leading Biotech companies who are expected to be major competitors in the COVID-19 vaccine market moving forward. Novavax shares traded lower in reaction to giving an update to a regulatory timeline of its COVID-19 vaccine, and posting first-quarter results that beat Wall Street estimates on May 10. Earlier this week, Novavax reached an agreement with the EC for the purchase of up to 200M doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant. The company's shares have gained more than 69% year to date. Recently, Cantor Fitzgerald raised

For further details see:

Novavax Q2 Earnings Preview